ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPGDrugs in Pipeline
17
Phase 3 Programs
8
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
How AAPG's past catalysts played out
Olverembatinib
GIST
APG-2575(Lisaftoclax )
Acute Myeloid Leukemia
Acalabrutinib
CLL/SLL
Imatinib
Ph+ ALL
Bosutinib
Chronic Myeloid Leukemia
lisaftoclax +BTK inhibitor
CLL/SLL
Lisaftoclax (APG-2575)
Relapsed/Refractory Acute Myeloid Leukaemia
Azacitidine Injection
Higher-risk Myelodysplastic Syndrome
Ibrutinib
Chronic Lymphocytic Leukemia
APG2575
Chronic Lymphocytic Leukemia
APG-115
AML
APG-1252
NHL, Adult
Phase 1b: APG-115+pembrolizumab
Unresectable or Metastatic Melanoma or Advanced Solid Tumors
HQP1351
Chronic Myeloid Leukemia, Chronic Phase
APG-1387 for Injection
Advanced Pancreatic Cancer
Toripalimab
Liposarcoma
APG-2575
T-Prolymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Olverembatinib | Phase 3 | GIST | - | - |
APG-2575(Lisaftoclax ) | Phase 3 | Acute Myeloid Leukemia | - | - |
Acalabrutinib | Phase 3 | CLL/SLL | - | - |
Imatinib | Phase 3 | Ph+ ALL | - | - |
Bosutinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
lisaftoclax +BTK inhibitor | Phase 3 | CLL/SLL | - | - |
Lisaftoclax (APG-2575) | Phase 3 | Relapsed/Refractory Acute Myeloid Leukaemia | - | - |
Azacitidine Injection | Phase 3 | Higher-risk Myelodysplastic Syndrome | - | - |
Ibrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
APG2575 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
APG-115 | Phase 2 | AML | - | - |
APG-1252 | Phase 2 | NHL, Adult | - | - |
Phase 1b: APG-115+pembrolizumab | Phase 2 | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | - | - |
HQP1351 | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase | - | - |
APG-1387 for Injection | Phase 2 | Advanced Pancreatic Cancer | - | - |
Toripalimab | Phase 2 | Liposarcoma | - | - |
APG-2575 | Phase 2 | T-Prolymphocytic Leukemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ASCENTAGE PHARMA GROUP INTERNATIONAL's drug pipeline?→
CatalystAlert tracks 17 drug candidates in ASCENTAGE PHARMA GROUP INTERNATIONAL's (AAPG) pipeline across Phase 3, Phase 2. Its lead program is Olverembatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ASCENTAGE PHARMA GROUP INTERNATIONAL's next FDA catalyst?→
ASCENTAGE PHARMA GROUP INTERNATIONAL's (AAPG) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AAPG biotech catalysts?→
Add AAPG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ASCENTAGE PHARMA GROUP INTERNATIONAL's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.